Valeant Pharmaceuticals International, Schering-Plough deal

Schering-Plough received an option to license exclusive rights in Japan to develop and commercialize Valeant's Viramidine taribavirin. The prodrug of ribavirin is in Phase II testing to treat HCV. In ...